TEAEs during prophylaxis with Wilate (safety analysis set, n = 43)
| Parameter . | n (%) . |
|---|---|
| Number of TEAEs | 78 |
| Patients with ≥1 TEAE | 26 (60.5) |
| Number of related∗ TEAE | 5 |
| Patients with ≥1 related∗ TEAE | 2 (4.7) |
| Discontinuations due to TEAE | 2 (4.7) |
| Number of serious TEAEs | 5 |
| Patients with ≥1 serious TEAE | 4 (9.3) |
| Patients with ≥1 related∗ serious TEAE | 0 (0.0) |
| Discontinuations due to serious TEAE | 0 (0.0) |
| Deaths due to TEAE | 0 (0.0) |
| Parameter . | n (%) . |
|---|---|
| Number of TEAEs | 78 |
| Patients with ≥1 TEAE | 26 (60.5) |
| Number of related∗ TEAE | 5 |
| Patients with ≥1 related∗ TEAE | 2 (4.7) |
| Discontinuations due to TEAE | 2 (4.7) |
| Number of serious TEAEs | 5 |
| Patients with ≥1 serious TEAE | 4 (9.3) |
| Patients with ≥1 related∗ serious TEAE | 0 (0.0) |
| Discontinuations due to serious TEAE | 0 (0.0) |
| Deaths due to TEAE | 0 (0.0) |
Assessed as probably or possibly related to the study treatment by the investigator.